NZ533237A - Flavivirus vaccine delivery system - Google Patents
Flavivirus vaccine delivery systemInfo
- Publication number
- NZ533237A NZ533237A NZ533237A NZ53323702A NZ533237A NZ 533237 A NZ533237 A NZ 533237A NZ 533237 A NZ533237 A NZ 533237A NZ 53323702 A NZ53323702 A NZ 53323702A NZ 533237 A NZ533237 A NZ 533237A
- Authority
- NZ
- New Zealand
- Prior art keywords
- protein
- replicon
- rna
- virus
- vaccine
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title claims abstract description 68
- 229960005486 vaccine Drugs 0.000 title claims description 75
- 208000015181 infectious disease Diseases 0.000 claims abstract description 49
- 241000700605 Viruses Species 0.000 claims abstract description 41
- 101710172711 Structural protein Proteins 0.000 claims abstract description 34
- 239000013604 expression vector Substances 0.000 claims abstract description 30
- 230000002458 infectious effect Effects 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims abstract description 28
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 238000003780 insertion Methods 0.000 claims abstract description 9
- 230000037431 insertion Effects 0.000 claims abstract description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 212
- 210000004027 cell Anatomy 0.000 claims description 143
- 230000014509 gene expression Effects 0.000 claims description 102
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 108020004414 DNA Proteins 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 241000710961 Semliki Forest virus Species 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 50
- 230000035772 mutation Effects 0.000 claims description 44
- 230000004044 response Effects 0.000 claims description 43
- 238000004806 packaging method and process Methods 0.000 claims description 40
- 241001465754 Metazoa Species 0.000 claims description 34
- 230000002163 immunogen Effects 0.000 claims description 32
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 23
- 241000710912 Kunjin virus Species 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 21
- 230000005867 T cell response Effects 0.000 claims description 20
- 241001529936 Murinae Species 0.000 claims description 16
- 101710189818 Non-structural protein 2a Proteins 0.000 claims description 16
- 230000001681 protective effect Effects 0.000 claims description 16
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 14
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 14
- 101800001030 Non-structural protein 2A Proteins 0.000 claims description 14
- 241000710960 Sindbis virus Species 0.000 claims description 14
- 101710144111 Non-structural protein 3 Proteins 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 11
- 230000007774 longterm Effects 0.000 claims description 11
- 101800000508 Non-structural protein 5 Proteins 0.000 claims description 9
- 101710144121 Non-structural protein 5 Proteins 0.000 claims description 9
- 239000012636 effector Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- -1 NS2B Proteins 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- 235000009582 asparagine Nutrition 0.000 claims description 7
- 229940009098 aspartate Drugs 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 101800000512 Non-structural protein 1 Proteins 0.000 claims description 6
- 101800000980 Protease nsP2 Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 101710204837 Envelope small membrane protein Proteins 0.000 claims description 5
- 101710145006 Lysis protein Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 101800001020 Non-structural protein 4A Proteins 0.000 claims description 5
- 210000004102 animal cell Anatomy 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 101710117545 C protein Proteins 0.000 claims description 4
- 101800001019 Non-structural protein 4B Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 150000003147 proline derivatives Chemical class 0.000 claims description 2
- 108010067390 Viral Proteins Proteins 0.000 claims 4
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 91
- 230000003053 immunization Effects 0.000 description 60
- 238000002649 immunization Methods 0.000 description 60
- 239000013598 vector Substances 0.000 description 56
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 52
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 49
- 230000010076 replication Effects 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 29
- 238000001890 transfection Methods 0.000 description 28
- 238000000338 in vitro Methods 0.000 description 27
- 230000006698 induction Effects 0.000 description 25
- 241000700618 Vaccinia virus Species 0.000 description 24
- 238000003556 assay Methods 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 16
- 238000010166 immunofluorescence Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000004520 electroporation Methods 0.000 description 15
- 210000004443 dendritic cell Anatomy 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 241000710929 Alphavirus Species 0.000 description 13
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 210000004988 splenocyte Anatomy 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 210000001672 ovary Anatomy 0.000 description 12
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 11
- 101710128560 Initiator protein NS1 Proteins 0.000 description 11
- 101710144127 Non-structural protein 1 Proteins 0.000 description 11
- 230000000120 cytopathologic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 230000002085 persistent effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 229950010131 puromycin Drugs 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 238000000636 Northern blotting Methods 0.000 description 8
- 230000003044 adaptive effect Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 108700004026 gag Genes Proteins 0.000 description 8
- 101150098622 gag gene Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108010041986 DNA Vaccines Proteins 0.000 description 7
- 229940021995 DNA vaccine Drugs 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 230000001024 immunotherapeutic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 101150033828 NS1 gene Proteins 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 101710177291 Gag polyprotein Proteins 0.000 description 4
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010012310 Dengue fever Diseases 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 229940022005 RNA vaccine Drugs 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000710886 West Nile virus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 208000025729 dengue disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101150098879 43 gene Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000707296 Alkhumra hemorrhagic fever virus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100036089 Fascin Human genes 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 108700004715 Flavivirus NS1 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101900222562 Influenza A virus Nucleoprotein Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000907325 Montana myotis leukoencephalitis virus Species 0.000 description 1
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
- 101500024857 Mus musculus Ubiquitin Proteins 0.000 description 1
- 101500025138 Mus musculus Ubiquitin Proteins 0.000 description 1
- 101500026511 Mus musculus Ubiquitin Proteins 0.000 description 1
- 101500027538 Mus musculus Ubiquitin Proteins 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 101500012568 Semliki forest virus Protease nsP2 Proteins 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000907517 Usutu virus Species 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 102000007362 alpha-Crystallins Human genes 0.000 description 1
- 108010007908 alpha-Crystallins Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000468 autoproteolytic effect Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 101150111388 pac gene Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 101150069452 z gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR9093A AUPR909301A0 (en) | 2001-11-26 | 2001-11-26 | Flavivirus vaccine system |
| AU2002950974A AU2002950974A0 (en) | 2002-07-29 | 2002-07-29 | Flavivirus vaccine system |
| PCT/AU2002/001598 WO2003046189A1 (en) | 2001-11-26 | 2002-11-26 | Flavivirus vaccine delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ533237A true NZ533237A (en) | 2005-11-25 |
Family
ID=25646850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ533237A NZ533237A (en) | 2001-11-26 | 2002-11-26 | Flavivirus vaccine delivery system |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060204523A1 (https=) |
| EP (1) | EP1461441A4 (https=) |
| JP (1) | JP2005510244A (https=) |
| CN (1) | CN100392087C (https=) |
| CA (1) | CA2467397A1 (https=) |
| NZ (1) | NZ533237A (https=) |
| WO (1) | WO2003046189A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004072274A1 (en) * | 2003-01-30 | 2004-08-26 | Shanghai Tengen Biomedical Co., Ltd. | Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier |
| AU2003902842A0 (en) * | 2003-06-06 | 2003-06-26 | The University Of Queensland | Flavivirus replicon packaging system |
| AU2004245578B2 (en) * | 2003-06-06 | 2008-10-30 | Replikun Biotech Pty Ltd | Flavivirus replicon packaging system |
| CN1304579C (zh) * | 2003-07-21 | 2007-03-14 | 上海天甲生物医药有限公司 | 重组的以黄热病病毒为载体的疫苗 |
| WO2005042014A1 (en) * | 2003-10-29 | 2005-05-12 | The University Of Queensland | West nile virus vaccine |
| UA101597C2 (uk) | 2006-02-27 | 2013-04-25 | Зе Боард Оф Регентс Оф Зе Універсіті Оф Тексас Сістем | Псевдоінфекційний флавівірус та його використання |
| AU2009223727B2 (en) | 2008-03-14 | 2014-09-11 | Sanofi Pasteur Biologics, Llc | Replication-defective flavivirus vaccines and vaccine vectors |
| EP2408477A4 (en) * | 2009-03-16 | 2013-03-27 | Sanofi Pasteur Biologics Llc | REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS |
| EP2590625B1 (en) * | 2010-07-06 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
| HRP20211595T1 (hr) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| HRP20191535T1 (hr) * | 2011-05-24 | 2019-11-29 | Biontech Rna Pharmaceuticals Gmbh | Individualizirana cjepiva protiv raka |
| WO2013019603A2 (en) * | 2011-07-29 | 2013-02-07 | Inovio Pharmaceuticals, Inc. | Linear expression cassettes and uses thereof |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| CA2999916C (en) * | 2015-09-23 | 2021-07-20 | Massachusetts Institute Of Technology | Compositions and methods for modified dendrimer nanoparticle vaccine delivery |
| WO2018152158A1 (en) * | 2017-02-14 | 2018-08-23 | Shi Pei Yong | Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| CN115038785A (zh) * | 2019-12-03 | 2022-09-09 | 昆士兰医学研究所理事会 | 缺陷型干扰颗粒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| HU228705B1 (en) * | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
| EP1034290A4 (en) * | 1997-11-28 | 2004-09-15 | Queensland Inst Med Res | FLAVIVIRUS-SPECIFIC EXPRESSION AND DIFFUSION SYSTEM |
| US6893866B1 (en) * | 1997-11-28 | 2005-05-17 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
| DE69942525D1 (de) * | 1998-09-02 | 2010-08-05 | Us Government | Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff |
| FR2794865B1 (fr) * | 1999-06-09 | 2003-04-18 | Pasteur Institut | Methode de detection precoce des flavivirus et ses applications |
| SK288290B6 (sk) * | 1999-08-09 | 2015-07-01 | Sandoz Ag | Vektor na expresiu heterológnych proteínov v bakteriálnej hostiteľskej bunke, bakteriálna hostiteľská bunka a spôsob produkcie požadovaného heterológneho polypeptidu |
| US6589531B1 (en) * | 2000-01-21 | 2003-07-08 | The Regents Of The University Of California | Recombinant yellow fever virus and method of use thereof |
| EP3000477A1 (en) * | 2000-02-16 | 2016-03-30 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Avirulent, immunogenic flavivirus chimeras |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
-
2002
- 2002-11-26 CA CA002467397A patent/CA2467397A1/en not_active Abandoned
- 2002-11-26 WO PCT/AU2002/001598 patent/WO2003046189A1/en not_active Ceased
- 2002-11-26 NZ NZ533237A patent/NZ533237A/en unknown
- 2002-11-26 CN CNB028275624A patent/CN100392087C/zh not_active Expired - Fee Related
- 2002-11-26 EP EP02779017A patent/EP1461441A4/en not_active Ceased
- 2002-11-26 US US10/496,421 patent/US20060204523A1/en not_active Abandoned
- 2002-11-26 JP JP2003547621A patent/JP2005510244A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1671851A (zh) | 2005-09-21 |
| CA2467397A1 (en) | 2003-06-05 |
| WO2003046189A1 (en) | 2003-06-05 |
| EP1461441A1 (en) | 2004-09-29 |
| JP2005510244A (ja) | 2005-04-21 |
| US20060204523A1 (en) | 2006-09-14 |
| HK1081987A1 (zh) | 2006-05-26 |
| CN100392087C (zh) | 2008-06-04 |
| EP1461441A4 (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101518309B1 (ko) | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 | |
| ES2588906T3 (es) | Casetes sin promotor para la expresión de proteínas estructurales de alfavirus | |
| CA2567254C (en) | Tc-83-derived alphavirus vectors, particles and methods | |
| Anraku et al. | Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity | |
| US20060204523A1 (en) | Flavivirus vaccine delivery system | |
| NO329693B1 (no) | Kimaerisk virus samt anvendelse derav, nukleinsyremolekyl og vaksinesammmensetning. | |
| US20060280757A1 (en) | Flavivirus vaccine delivery system | |
| JP7240029B2 (ja) | フラビウイルスとリッサウイルスとのキメラワクチン | |
| US20070036827A1 (en) | West nile virus vaccine | |
| JP2019535291A (ja) | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン | |
| Anraku et al. | Kunjin replicon-based simian immunodeficiency virus gag vaccines | |
| AU2002342415B2 (en) | Flavivirus vaccine delivery system | |
| HK1081987B (en) | Flavivirus vaccine delivery system | |
| RU2816136C2 (ru) | Химерные вакцины на основе вирусов родов flavivirus и lyssavirus | |
| AU2004245578B2 (en) | Flavivirus replicon packaging system | |
| US20200316187A1 (en) | Chimeric yellow fever zika virus strain | |
| EP4041301A1 (en) | Chimeric filovirus vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: REPLIKUN BIOTECH PTY LTD, AU Free format text: OLD OWNER(S): THE UNIVERSITY OF QUEENSLAND; THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH |